Cargando…

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Manger, Jules P., Krupski, Tracey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2012
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708213/ https://www.ncbi.nlm.nih.gov/pubmed/26816696 http://dx.doi.org/10.3978/j.issn.2223-4683.2012.05.08

Ejemplares similares

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
por: Wolff, Johannes M., et al.
Publicado: (2012)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
por: Ohlmann, Carsten-Henning
Publicado: (2012)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Ailanthone: a new potential drug for castration-resistant prostate cancer
por: Peng, Shihong, et al.
Publicado: (2017)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Yoshida, Soichiro, et al.
Publicado: (2021)

Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
por: Suzuki, Kazuhiro, et al.
Publicado: (2021)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis
por: Blee, Alexandra M., et al.
Publicado: (2016)

Partial Nephrectomy in a Patient with a Left Ventricular Assist Device
por: Manger, Jules P., et al.
Publicado: (2011)

Editorial Comment to Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Hirayama, Yukiyoshi, et al.
Publicado: (2021)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bq02ih7tslhlohgdmvq6nv42b3